Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

June 1, 2011

Primary Completion Date

April 16, 2012

Study Completion Date

April 16, 2012

Conditions
Reduction in Hypertrophic Skin Scarring
Interventions
DRUG

EXC 001

Single-dose administered by injection four different times

DRUG

EXC 001

Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1

DRUG

EXC 001

Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2

DRUG

EXC 001

Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3

Trial Locations (12)

33133

Bayside Ambulatory Center, Miami

33146

Aesthetic Plastic Surgery Miami, Miami

33461

Altus Research, Lake Worth

63141

Body Aesthetic Plastic Surgery, St Louis

78229

Endeavor Clinical Trials,P.A., San Antonio

90602

Bright Health Physicans Plastic Surgery and Aesthetic Medicine, Whittier

91105

Skin Deep Laser Medical Spa, Pasadena

97062

Connall Consmetic Surgery, Tualatin

97401

Mark L. Jewell,MD Surgery Center, Eugene

98043

BAXTER Plastic Surgery, Mountlake Terrace

07042

New Jersey Plastic Surgery, Montclair

78240-1670

Texas Plastic Surgery, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01346969 - Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery | Biotech Hunter | Biotech Hunter